BackgroundCheck.run
Search For

Peter Edward Haroldsen, 661407 Crespi Dr, Sharp Park, CA 94044

Known as:
Peter E Haroldsen Peter E Harolosen Peter Haroldson Peter Eames
Related to:
Carolyn F Souhrada 58

Peter Haroldsen Phones & Addresses

1407 Crespi Dr, Pacifica, CA 94044    650-7388052   

Irvine, CA   

Vista, CA   

Oceanside, CA   

Palo Alto, CA   

Minneapolis, MN   

Newport Beach, CA   

Mountain View, CA   

San Diego, CA   

Houston, TX   

1407 Crespi Dr, Pacifica, CA 94044    650-2080001   

Education

Degree: High school graduate or higher

Emails

p***[email protected]
Get Report
Control this profile

Mentions for Peter Edward Haroldsen

Peter Haroldsen resumes & CV records

Resumes

Peter Haroldsen Photo 12

Director Dmpk

Industry:
Pharmaceuticals
Work:
Cortex Pharmaceuticals
Director Dmpk
Peter Haroldsen Photo 13

Director Dmpk At Cortex Pharmaceuticals

Position:
director DMPK at Cortex Pharmaceuticals
Location:
Orange County, California Area
Industry:
Pharmaceuticals
Work:
Cortex Pharmaceuticals
director DMPK

Publications & IP owners

Us Patents

Methods Of Treating Cancer And Related Methods

US Patent:
2004022, Nov 4, 2004
Filed:
Nov 12, 2003
Appl. No.:
10/706328
Inventors:
Alison Hannah - Sebastopol CA, US
Eric Harwood - Seattle WA, US
Peter Haroldsen - Pacifica CA, US
Carla Heise - Benecia CA, US
Timothy Machajewski - Martinez CA, US
Emil Samara - Danville CA, US
Xiao Shang - Bellevue WA, US
Jayesh Vora - Martinez CA, US
Shuguang Zhu - Seattle WA, US
Assignee:
Chiron Corporation
International Classification:
A61K031/496
US Classification:
514/253070
Abstract:
Methods of treating cancer using 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1 -yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one are provided. In particular, the methods are effective for the treatment of solid tumors or leukemias, including prostate, colorectal, breast, multiple myeloma, pancreatic, small cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, or myelo-proliferative disease. Further provided are methods of measuring the amount of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1 -yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one and determining a metabolic profile therefore.

Methods Of Administering 3,4-Diaminopyridine

US Patent:
2023003, Feb 2, 2023
Filed:
Mar 4, 2022
Appl. No.:
17/686895
Inventors:
- Bruxelles, BE
Peter E. HAROLDSEN - Pacifica CA, US
Donald G. MUSSON - Larkspur CA, US
International Classification:
C12Q 1/48
G01N 33/564
A61K 31/44
A61K 38/45
C12Q 1/6883
Abstract:
Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceuticaliy acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.

Methods Of Administering 3,4-Diaminopyridine

US Patent:
2021000, Jan 7, 2021
Filed:
Sep 18, 2020
Appl. No.:
17/025909
Inventors:
- Bruxelles, BE
Peter E. HAROLDSEN - Pacifica CA, US
Donald G. MUSSON - Larkspur CA, US
International Classification:
C12Q 1/48
G01N 33/564
A61K 31/44
A61K 38/45
C12Q 1/6883
Abstract:
Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.

Methods Of Administering 3,4-Diaminopyridine

US Patent:
2021000, Jan 7, 2021
Filed:
Sep 18, 2020
Appl. No.:
17/025918
Inventors:
- Bruxelles, BE
Peter E. HAROLDSEN - Pacifica CA, US
Donald G. MUSSON - Larkspur CA, US
International Classification:
C12Q 1/48
G01N 33/564
A61K 31/44
A61K 38/45
C12Q 1/6883
Abstract:
Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.

Methods Of Administering 3,4-Diaminopyridine

US Patent:
2020040, Dec 31, 2020
Filed:
Sep 1, 2020
Appl. No.:
17/009250
Inventors:
- Bruxelles, BE
Peter E. HAROLDSEN - Pacifica CA, US
Donald G. MUSSON - Larkspur CA, US
International Classification:
C12Q 1/48
G01N 33/564
A61K 31/44
A61K 38/45
C12Q 1/6883
Abstract:
Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.

Methods Of Administering 3,4-Diaminopyridine

US Patent:
2020040, Dec 31, 2020
Filed:
Sep 1, 2020
Appl. No.:
17/009261
Inventors:
- Bruxelles, BE
Peter E. HAROLDSEN - Pacifica CA, US
Donald G. MUSSON - Larkspur CA, US
International Classification:
C12Q 1/48
G01N 33/564
A61K 31/44
A61K 38/45
C12Q 1/6883
Abstract:
Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt hereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.

Methods Of Administering 3, 4-Diaminopyridine

US Patent:
2014025, Sep 11, 2014
Filed:
Jun 29, 2012
Appl. No.:
14/128672
Inventors:
Marvin R. Garovoy - Sausalito CA, US
Peter E. Haroldsen - Pacifica CA, US
Donald G. Musson - Larkspur CA, US
Assignee:
BIOMARIN PHARMACEUTICALS, INC. - Novato CA
International Classification:
C12Q 1/48
A61K 38/45
C12Q 1/68
A61K 31/44
US Classification:
424 945, 514352, 546307, 435 611, 435 15
Abstract:
Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.

Possible Relatives

David G Haroldsen  Deborah Haroldsen  Daniel S Haroldsen  Jon M Haroldsen  Michael J Haroldsen  Robert G Haroldsen  Tad J Haroldsen  Peter L Johnson  Peter J Stan  Peter Stanczak 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.